Followers | 145 |
Posts | 27566 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Tuesday, April 20, 2021 9:06:29 AM
Kamada's CEO explains the secret to Israel's success against the virus
Apr 20, 2021, 06:15 ET
MILAN, April 20, 2021 /PRNewswire/ -- Amir London, the CEO of Israel's Kamada Ltd., a plasma-derived biopharmaceutical company, said Kamada and its Italian partner Kedrion Biopharma are forging ahead with the development of a new anti-Covid therapy derived from the plasma of convalescent patients. The therapy is already being used in Israel.
The Kamada CEO, in an interview with the Milan-based Le Fonti TV, said on Tuesday that he hoped that discussions with various health authorities and regulators around the world would soon help make available the new therapy in other countries.
"We start with raw material which is human plasma collected by Kedrion in the United States," Mr. London explained. "Our technology allows us to purify the plasma into specific proteins and antibodies called immunoglobulins and this is used for all kinds of rare diseases. Since the Covid-19 pandemic started we have been very focused in working together with Kedrion Biopharma on developing a very innovative approach to Covid by using convalescent plasma, which is the plasma from recovered patients, in order to purify specific antibodies against Covid for the therapeutic treatment of hospital patients."
Kamada has been working with Israel's health ministry in recent months and now offers the therapy in Israel to treat Covid-19 patients.
Asked by Alessia Liparoti of Le Fonti TV what is the secret to Israel's success in vaccinating its population, Mr. London explained: "Israel was among the first to sign agreements, primarily with Pfizer, for the supply of vaccines. We were among the first countries to get a significant supply. Israel has a hybrid health system that combines national coverage for all patients with strong HMOs and health funds. Israel also has strong logistical abilities and being a relatively small country in size allows us to reach the entire population within hours. Every Israeli can get to a medical center within minutes. So, the logistic supply chain has been very effective, and this is helping us to reopen the economy."
Regarding its collaboration with Kedrion, the Israeli executive said: "Our relationship with Kedrion goes many years back and we are very happy with the relationship. We have been working in the US market on other treatments, including one against rabies. When Covid started last year, we decided to expand that relationship to Covid products, and we are developing the therapy together. Kamada is responsible for the manufacturing and the clinical development while Kedrion is working on collecting the plasma from recovered patients in the United States and on supporting the development work. We are very happy with this successful cooperation, and in terms of the future we are in discussion with multiple health authorities and regulators around the world on making it available also in other countries."
Recent KMDA News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/08/2024 11:00:49 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/06/2024 12:10:12 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/28/2024 12:00:02 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 05:41:57 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 12/28/2023 06:16:03 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/28/2023 02:30:02 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 12/19/2023 11:00:37 AM
- KEDRION ANNOUNCES AN EIGHT-YEAR EXTENSION OF THE DISTRIBUTION AGREEMENT WITH KAMADA IN THE US FOR KEDRAB® • PR Newswire (US) • 12/07/2023 04:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/06/2023 12:00:04 PM
- Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] • Edgar (US Regulatory) • 11/13/2023 03:04:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/13/2023 01:00:04 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/13/2023 12:00:29 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/08/2023 12:00:31 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/16/2023 11:00:13 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/10/2023 11:30:16 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/15/2023 04:15:27 AM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 09/11/2023 11:01:06 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/30/2023 11:00:02 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/16/2023 11:00:37 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/09/2023 11:00:09 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/13/2023 08:05:59 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/12/2023 11:00:16 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM